Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis

Figure 1 Detailed information on the patients that were included for analysis.

Figure 2 Impedance aggregometry and thrombelastometry in patients with mild and severe liver cirrhosis. A: Box and whisker plots of impedance aggregometry: Results are presented for area under the curve (AUC) of ADP (a), AUC_ASPI (b) and AUC_TRAP (c); B: Box and whisker plots of thrombelastometry: Presented are results of EXTEM clotting time (CT) (a), EXTEM clot formation time (b), EXTEM maximum clot firmness (MCF) (c), EXTEM α-angle (d), INTEM CT (e), INTEM clot formation time (f), INTEM MCF (g), INTEM α-angle (h), FIBTEM CT (i) and FIBTEM MCF (j). The lower and upper bars represent the minimum and maximum, respectively. The lower and upper ends of the box represent the 25^th and 75^th percentiles, respectively; the line in the box represents the median. Data comparisons were made using Mann-Whitney U-test. ADP: Adenosine-5 diphosphate; ASPI: Arachidonic acid; TRAP: Thrombin receptor activator peptide 6; MELD: Model for end-stage liver disease; CT: Clotting time; CFT: Clot formation time; MCF: Maximum clot firmness.

Figure 3 Spearman rank correlation analysis and linear regression line fitting of area under the curve of impedance aggregometric assays. A-C: Scatterplots illustrating the relationship between platelet count and area under the curve (AUC, U) of impedance aggregometric assay: ADP-test (A), ASPI-test (B), TRAP-test (C); D-F: Scatterplots illustrating the relationship between model for end-stage liver disease score and AUC (U) of impedance aggregometric assay: ADP-test (D), ASPI-test (E), TRAP-test (F). Spearman rank correlation coefficients (R²) between model for end-stage liver disease score and AUC of impedance aggregometry with P values are given for each test. The upper and lower reference ranges of AUC are highlighted in the grey area. AUC: Area under the curve; ADP: Adenosine-5 diphosphate; ASPI: Arachidonic acid; TRAP: Thrombin receptor activator peptide 6; MELD: Model for end-stage liver disease.

Figure 4 Spearman rank correlation analysis and linear regression line fitting between model for end-stage liver disease score and results of thrombelastometry. Scatterplots illustrating the relationship between model for end-stage liver disease score and results of thrombelastometry: A: EXTEM clotting time (CT); B: EXTEM maximum clot firmness (MCF); C: EXTEM clot formation time; D: ECTEM α-angle; E: INTEM CT; F: INTEM MCF; G: INTEM clot formation time; H: INTEM α-angle; I: FIBTEM CT; and J: FIBTEM MCF. Spearman rank correlation coefficients squared (R²) between model for end-stage liver disease score and AUC of impedance aggregometry and linear regression with P values are given for each test. The upper and lower reference ranges of area under the curve are highlighted in the grey area. CT: Clotting time; CFT: Clot formation time; MCF: Maximum clot firmness; MELD: Model for end-stage liver disease.